Cannabidiol prevents a post-ischemic injury progressively induced by cerebral ischemia via a high-mobility group box1-inhibiting mechanism

Neuropharmacology

Volumn 55, Issue 8, 2008, Pages 1280-1286

  Hayakawa, Kazuhide ^a   Mishima, Kenichi ^a   Irie, Keiichi ^a   Hazekawa, Mai ^a   Mishima, Shohei ^a   Fujioka, Masayuki ^a   Orito, Kensuke ^b   Egashira, Nobuaki ^a   Katsurabayashi, Shutaro ^a   Takasaki, Kotaro ^a   Iwasaki, Katsunori ^a   Fujiwara, Michihiro ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b AZABU UNIVERSITY   (Japan)

Author keywords

Cannabidiol; Cerebral ischemia; High mobility group box1; Myeloperoxidase

Indexed keywords

6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; CANNABIDIOL; HIGH MOBILITY GROUP B1 PROTEIN; MYELOPEROXIDASE; PROTEIN INHIBITOR; RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN INFARCTION SIZE; BRAIN INJURY; BRAIN ISCHEMIA; BRAIN PROTECTION; CELL ACTIVATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL MODEL; IMMUNOHISTOCHEMISTRY; MALE; MICROGLIA; MIDDLE CEREBRAL ARTERY OCCLUSION; MOTOR COORDINATION; MOUSE; NEUROLOGIC EXAMINATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REPERFUSION; ROTAROD TEST;

ANALYSIS OF VARIANCE; ANIMALS; BLOOD PRESSURE; BRAIN INJURIES; CALCIUM-BINDING PROTEINS; CANNABIDIOL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; HMGB1 PROTEIN; IN SITU NICK-END LABELING; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MICE; MOTOR ACTIVITY; NEUROLOGIC EXAMINATION; PEROXIDASE; PHOSPHOPYRUVATE HYDRATASE; REPERFUSION; TETRAZOLIUM SALTS; TIME FACTORS;

EID: 56249131093     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2008.06.040     Document Type: Article

References (30)

1. Abraham E., Arcaroli J., Carmody A., Wang H., and Tracey K.J. HMG-1 as a mediator of acute lung inflammation. J. Immunol. 165 (2000) 2950-2954
2. Baker D., Pryce G., Davies W.L., and Hiley C.R. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol. Sci. 27 (2006) 1-4
3. Begg M., Pacher P., Batkai S., Osei-Hyiaman D., Offertaler L., Mo F.M., Liu J., and Kunos G. Evidence for novel cannabinoid receptors. Pharmacol. Ther. 106 (2005) 133-145
4. Bianchi M.E., and Manfredi A.A. High-mobility group box1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol. Rev. 220 (2007) 35-46
5. Bradley P.P., Priebat D.A., Christensen R.D., and Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J. Invest. Dermatol. 78 (1982) 206-209
6. Carrier E.J., Auchampach J.A., and Hillard C.J. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 7895-7900
7. Chen Y., and Buck J. Cannabinoids protect cells from oxidative cell death: a receptor-independent mechanism. J. Pharmacol. Exp. Ther. 293 (2000) 807-812
8. Consroe P., Laguna J., Allender J., Snider S., Stern L., Sandyk R., Kennedy K., and Schram K. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol. Biochem. Behav. 40 (1991) 701-708
9. Cunha J.M., Carlini E.A., Pereira A.E., Ramos O.L., Pimentel C., Gafliardi R., Sanvito W.L., Lander N., and Mechoulam R. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21 (1980) 175-185
10. Egashira N., Iwasaki K., Takashima A., Watanabe T., Kawabe H., Matsuda T., Mishima K., Chidori S., Nishimura R., and Fujiwara M. Altered depression-related behavior and neurochemical changes in serotonergic neurons in mutant R406W human tau transgenic mice. Brain Res. 1059 (2005) 7-12
11. EI-Remessy A.B., AI-Shabrawey M., Khalifa Y., Tsai N.T., Caldwell R.B., and Liou G.I. Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am. J. Pathol. 168 (2006) 235-244
12. Esposito G., Scuderi C., Savani C., Steardo Jr. L., De Filippis D., Cottone P., Iuvone T., and Steardo L. Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. Br. J. Pharmacol. 151 (2007) 1272-1279
13. Hampson A.J., Grimaldi M., Axelrod J., and Wink D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 8268-8273
14. Hampson A.J., Grimaldi M., Lolic M., Wink D., Rosenthal R., and Axelrod J. Neuroprotective antioxidants from marijuana. Ann. N.Y. Acad. Sci. 899 (2000) 274-282
15. Hayakawa K., Mishima K., Abe K., Hasebe N., Takamatsu F., Yasuda H., Ikeda T., Inui K., Egashira N., Iwasaki K., and Fujiwara M. Cannabidiol prevents infarction via non-CB1 cannabinoid receptor mechanism. Neuroreport 15 (2004) 2381-2385
16. Hayakawa K., Mishima K., Nozako M., Hazekawa M., Irie K., Fujioka M., Orito K., Abe K., Hasebe N., Egashira N., Iwasaki K., and Fujiwara M. Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism. J. Neurochem. 102 (2007) 1488-1496
17. Hayakawa K., Mishima K., Nozako M., Hazekawa M., Mishima S., Fujioka M., Orito K., Egashira N., Iwasaki K., and Fujiwara M. Delayed treatment with minocycline improves neurological impairment via activated microglia expressing high-mobility group box1 inhibiting mechanism. Stroke 39 (2008) 951-958
18. Huttunen H.J., and Rauvala H. Amphoterin as an extracellular regulator of cell motility: from discovery to disease. J. Intern. Med. 255 (2004) 351-366
19. Kim J.B., Sig Choi J., Yu Y.M., Nam K., Piao C.S., Kim S.W., Lee M.H., Han P.L., Park J.S., and Lee J.K. HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. J. Neurosci. 26 (2006) 6413-6421
20. Klein T.W. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat. Rev. Immunol. 5 (2005) 400-411
21. Lue L.F., Walker D.G., and Rogers J. Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures. Neurobiol. Aging 22 (2001) 945-956
22. McMillen T.S., Heinecke J.W., and LeBoeuf R.C. Expression of human myeloperoxidase by macrophages promotes atherosclerosis in mice. Circulation 111 (2005) 2798-2804
23. 1A receptor-dependent mechanism. Stroke 36 (2005) 1071-1076
24. Park I.H., Yeon S.I., Youn J.H., Choi J.E., Sasaki N., Choi I.H., and Shin J.S. Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. Mol. Immunol. 40 (2004) 1203-1211
25. Rajesh M., Mukhopadhyay P., Batkai S., Hasko G., Liaudet L., Drel V.R., Obrosova I.G., and Pacher P. Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. Am. J. Physiol. Heart Circ. Physiol. 293 (2007) H610-H619
26. Riuzzi F., Sorci G., and Donato R. The amphoterin (HMGB1)/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness. Functional inactivation of RAGE in L6 myoblasts results in tumor formation in vivo. J. Biol. Chem. 281 (2006) 8242-8253
27. Sobajima J., Ozaki S., Osakada F., Uesugi H., Shirakawa H., Yoshida M., and Nakao K. Novel autoantigens of perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) in ulcerative colitis: non-histone chromosomal proteins, HMG1 and HMG2. Clin. Exp. Immunol. 107 (1997) 135-140
28. Walter L., Franklin A., Witting A., Wade C., Xie Y., Kunos G., Mackie K., and Stella N. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J. Neurosci. 23 (2003) 1398-1405
29. Wang H., Bloom O., Zhang M., Vishnubhakat J.M., Ombrellino M., Che J., Frazier A., Yang H., Ivanova S., Borovikova L., Manogue K.R., Faist E., Abraham E., Andersson J., Andersson U., Molina P.E., Abumrad N.N., Sama A., and Tracey K.J. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285 (1999) 248-251
30. Wiley J.L., and Martin B.R. Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes. Chem. Phys. Lipids 121 (2002) 57-63